Blau Farmaceutica SABMFBOVESPA: BLAU3

Blau Farmacêutica: Biosimilars and mAbs drive transformational growth, supported by expansion and innovation

· Issued by Blau Farmaceutica SA

A leading pharmaceutical company in Latin America, with strong hospital segment leadership, is driving growth through biosimilars, especially monoclonal antibodies, and expanding production capacity and international presence. Strategic investments and robust governance support its ambition for global reach.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Blau Farmaceutica SA on 6ix

Earlier from Blau Farmaceutica

Later from Blau Farmaceutica

All Blau Farmaceutica news releases